FOLH1 and prostate adenocarcinoma: By comparison, high tumors ADs has been recently evaluated as up to 468 Gy with radionuclide therapy using 177Lu-PSMA to treat prostate adenocarcinoma metastases, with great impact on disease-free survival [35].